logo

Alkermes Plc (ALKS)



Trade ALKS now with
  Date
  Headline
1/14/2021 7:04:18 AM Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion For Treatment Of MUD Published
1/6/2021 7:02:55 AM Alkermes Names Blair Jackson COO And Iain Brown CFO
12/29/2020 7:02:03 AM FDA Accepts Alkermes' Resubmission Of NDA For ALKS 3831; FDA Sets PDUFA Target Action Date Of June 1, 2021
12/10/2020 7:02:17 AM Alkermes Announces Profitability Targets & Cost Structure Optimization Efforts
11/17/2020 7:06:13 AM Alkermes Receives FDA CRL For ALKS 3831 For Adults With Schizophrenia And Adults With Bipolar I Disorder
10/29/2020 7:07:37 AM Alkermes plc (ALKS) Has Raised Its FY20 Revenue Estimate To $1,010 – $1,035 Mln From $965 – $1,005 Mln
10/29/2020 7:02:06 AM Alkermes Plc Reports Q3 Breakeven Per Share; Non-GAAP EPS Of $0.26
10/9/2020 7:06:40 AM Alkermes Says Nasdaq Halts Trading Of Company's Ordinary Shares